Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 11/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31310689 | 1.00 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2HTTCNR2MEN1 | |
| SCHEMBL5138492 | 0.93 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2HTTCNR2MEN1 | |
| SCHEMBL5754979 | 0.88 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2HTTCNR2MEN1 | |
| SCHEMBL31547032 | 0.82 | CYP1A2 (0.52) | ALDH1A1SMN1; SMN2HTTCNR2NPC1 | |
| SCHEMBL29292349 | 0.80 | CYP1A2 (0.60) | ALDH1A1SMN1; SMN2HTTCNR2NPC1 | |
| SCHEMBL24921457 | 0.78 | CNR2 (0.58) | ALDH1A1SMN1; SMN2HTTCNR2MEN1 | |
| SCHEMBL21815357 | 0.77 | BPTF (0.62) | ALDH1A1HTTKDM4EHSD17B10 | |
| SCHEMBL807738 | 0.77 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2HTTCNR2MEN1 | |
| SCHEMBL21423998 | 0.77 | BPTF (0.62) | ALDH1A1SMN1; SMN2HTTCNR2MEN1 | |
| SCHEMBL31047535 | 0.77 | MEN1 (0.54) | ALDH1A1SMN1; SMN2HTTCNR2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12472181-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2025-11-18 | — | — | US | disclosed |
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2025-04-01 | — | — | US | disclosed |
| US-12258328-B2 | 6-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors | YUHAN CORPORATION (KR) | 2025-03-25 | — | — | US | disclosed |
| US-20240368104-A1 | Novel Dialkoxynaphtho[2,3-C]Furan-1(3H)-One Derivatives and Pharmaceutical Composition For Preventing or Treating Respiratory Disease or SARS-COV-2 Infection Disease, Comprising Same | DONG WHA PHARM. CO., LTD. (KR) | 2024-11-07 | — | — | US | disclosed |
| US-20240325404-A1 | TREATMENT OF INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2024-10-03 | — | — | US | disclosed |
| WO-2024153617-A1 | PHARMACEUTICAL COMPOSITIONS AND SOLID FORMS OF COMPOUND 1 WITH FUMARATE FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2024-07-25 | — | — | WO | disclosed |
| EP-3735411-B1 | 1,3,4,5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER`S DISEASE | AC IMMUNE SA (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-4370128-A1 | TREATMENT OF INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2024-05-22 | — | — | EP | disclosed |
| CN-117677387-A | Treatment of inflammatory diseases | 加拉帕戈斯股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-117534670-A | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | 加拉帕戈斯股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| US-20190211012-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2019-07-11 | — | — | US | disclosed |
| WO-2019134978-A1 | 1, 3, 4, 5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER'S DISEASE | AC IMMUNE SA (CH) | 2019-07-11 | — | — | WO | disclosed |
| WO-2019076716-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2019-04-25 | — | — | WO | disclosed |
| WO-2019076716-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2019-04-25 | — | — | WO | disclosed |
| US-20190112290-A1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | Propellon Therapeutics Inc. (CA) | 2019-04-18 | — | — | US | disclosed |
| EP-3423451-A1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | Propellon Therapeutics Inc. (CA) | 2019-01-09 | — | — | EP | disclosed |
| WO-2008116816-A1 | COMBINATION OF CB2 LIGAND AND PARACETAMOL | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116816-A1 | COMBINATION OF CB2 LIGAND AND PARACETAMOL | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
| WO-2007022937-A1 | PYRIDAZINE DERIVATIVES WITH ANTIINFLAMMATORY ACTIVITY | GLAXO GROUP LIMITED (GB) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007022937-A1 | PYRIDAZINE DERIVATIVES WITH ANTIINFLAMMATORY ACTIVITY | GLAXO GROUP LIMITED (GB) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325404-A1 | TREATMENT OF INFLAMMATORY DISEASES | IFNAR1, IFNG, IRF3 | ALDH1A1 1754/4885SMN1; SMN2 1577/4885HTT 1215/4885 |
| US-20190211012-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, MAP1LC3B | ALDH1A1 3543/4885SMN1; SMN2 445/4885HTT 18/4885 |
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | WDR5, WDR82, WDR1 | ALDH1A1 3236/4885SMN1; SMN2 1883/4885HTT 3462/4885 |
| US-20240368104-A1 | Novel Dialkoxynaphtho[2,3-C]Furan-1(3H)-One Derivatives and Pharmaceutical Composition For Preventing or Treating Respiratory Disease or SARS-COV-2 Infection Disease, Comprising Same | IL5, ACE2, IL15 | ALDH1A1 525/4885SMN1; SMN2 4180/4885HTT 2726/4885 |
| US-20190112290-A1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | WDR5, WDR82, WDR1 | ALDH1A1 3562/4885SMN1; SMN2 1705/4885HTT 2694/4885 |
| US-12472181-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | IL15, IL2, IL33 | ALDH1A1 784/4885SMN1; SMN2 3211/4885HTT 776/4885 |
| US-12258328-B2 | 6-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors | EGFR, ERBB2, ERBB4 | ALDH1A1 3020/4885SMN1; SMN2 4608/4885HTT 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.